Assertio Therapeutics, Inc. (NASDAQ:ASRT) is set to announce third quarter earning results on Friday 6th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, ASRT to report 3Q20 income of $ 0.01 per share.
For the full year, analysts anticipate top line of $ 109.30 million, while looking forward to income of $ 0.17 per share bottom line.
Previous Quarter Performance
Assertio Therapeutics, Inc. communicated loss for the second quarter of $ 0.28 per share, from the revenue of $ 20.62 million. The quarterly revenues down 63.95 percent compared with the same quarter last year. Wall street analysts are predicting, ASRT to report 2Q20 loss of $ 0.03 per share from revenue of $ 25.33 million. The top line results fell short of analysts by $ 4.71 million or 18.59 percent.
Stock Performance
Shares of Assertio Therapeutics, Inc. traded up $ 0.02 or 2.90 percent on Thursday, reaching $ 0.67 with volume of 177.90 thousand shares. Assertio Therapeutics, Inc. has traded high as $ 0.67 and has cracked $ 0.64 on the downward trend
According to the previous trading day, closing price of $ 0.67, representing a 18.18 % increase from the 52 week low of $ 0.55 and a 61.99 % decrease over the 52 week high of $ 1.71.
The company has a market capital of $ 71.77 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Assertio Therapeutics, Inc. will be hosting a conference call at 8:30 AM eastern time on 6th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.assertiotx.com
Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The company offers Gralise (gabapentin), a once daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; and Zipsor (diclofenac potassium liquid filled capsules), a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain. It also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to require daily, around-the-clock, and long term opioid treatment, including neuropathic pain related to diabetic peripheral neuropathy in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults.
